NO924138D0 - CHINOLINE DERIVATIVES, THE PROCEDURE FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION - Google Patents

CHINOLINE DERIVATIVES, THE PROCEDURE FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION

Info

Publication number
NO924138D0
NO924138D0 NO924138A NO924138A NO924138D0 NO 924138 D0 NO924138 D0 NO 924138D0 NO 924138 A NO924138 A NO 924138A NO 924138 A NO924138 A NO 924138A NO 924138 D0 NO924138 D0 NO 924138D0
Authority
NO
Norway
Prior art keywords
group
alkoxy
procedure
preparation
aryl
Prior art date
Application number
NO924138A
Other languages
Norwegian (no)
Other versions
NO924138L (en
Inventor
Gerard Cremer
Pascale Goberville
Jean-Claude Muller
Original Assignee
Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9418349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO924138(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synthelabo filed Critical Synthelabo
Publication of NO924138D0 publication Critical patent/NO924138D0/en
Publication of NO924138L publication Critical patent/NO924138L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Communication Cables (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Compounds corresponding to the formula (I) <IMAGE> in which, R1 represents either a 1H-tetrazol-5-yl group or a CO2H group, R2 represents either a (C1-7)alkyl group or a (C2-6)alkenyl group, R3 and R4 represent, each independently of the other, either a hydrogen atom, or a halogen atom, or a cyano group, or a (C1-7)alkyl group, or a (C3-7)cycloalkyl(C1-4)alkyl group, or an aryl group, or an aryl(C1-4)alkyl group, or an aryl(C2-4)alkenyl group, or a group -(CH2)mCOR5 in which m = 0 to 4 and R5 represents a hydrogen atom, an OH group, a (C1-6)alkoxy group or a group NR7R8, R7 and R8 representing, each independently of the other, a hydrogen atom or a (C1-4)alkyl group, or R3 and R4 represents, each independently of the other, a group -(CH2)n-R6 in which n = 1 to 4 and R6 represents an OH group, a (C1-6)alkoxy group, a (C1-4)alkoxy(C1-4)alkoxy group or a (C3-7)cycloalkyl(C1-4)alkoxy group, and their pharmaceutically acceptable organic or inorganic salts. Application in therapeutics.
NO92924138A 1991-10-28 1992-10-27 CHINOLINE DERIVATIVES, THE PROCEDURE FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION NO924138L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9113240A FR2683819B1 (en) 1991-10-28 1991-10-28 QUINOLEIN DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION.

Publications (2)

Publication Number Publication Date
NO924138D0 true NO924138D0 (en) 1992-10-27
NO924138L NO924138L (en) 1993-04-29

Family

ID=9418349

Family Applications (1)

Application Number Title Priority Date Filing Date
NO92924138A NO924138L (en) 1991-10-28 1992-10-27 CHINOLINE DERIVATIVES, THE PROCEDURE FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION

Country Status (18)

Country Link
EP (1) EP0540400B1 (en)
JP (1) JPH05239053A (en)
KR (1) KR930007935A (en)
CN (1) CN1073171A (en)
AT (1) ATE126798T1 (en)
AU (1) AU651740B2 (en)
CA (1) CA2081537A1 (en)
CZ (1) CZ324292A3 (en)
DE (1) DE69204252T2 (en)
FI (1) FI924869A (en)
FR (1) FR2683819B1 (en)
HU (1) HUT62883A (en)
IL (1) IL103568A0 (en)
MX (1) MX9206169A (en)
NO (1) NO924138L (en)
NZ (1) NZ244892A (en)
PL (1) PL296369A1 (en)
ZA (1) ZA928297B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478832A (en) * 1992-05-08 1995-12-26 The Green Cross Corporation Quinoline compounds
IT1255461B (en) * 1992-07-28 1995-11-02 Luso Farmaco Inst ETHERS OF IMIDAZOLI ACTIVATED IN II ANTAGONIST
FR2699174B1 (en) * 1992-12-14 1995-01-20 Synthelabo Derivatives of 3- (quinoline-6-yl-methyl) -4H-imidazol-4-one, their preparation and their therapeutic use.
FR2710914B1 (en) * 1993-10-04 1995-11-24 Synthelabo 2- [2- (tetrazol-5-yl) phenyl] -1,2-dihydroquinoline derivatives, their preparation and their use as synthesis intermediates.
FR2716196B1 (en) * 1994-02-16 1996-04-05 Synthelabo 8- [2- (1H-tetrazol-5-yl) phenyl] quinoline derivatives, their preparation and their therapeutic use.
JPH09202774A (en) 1996-01-25 1997-08-05 Green Cross Corp:The 2-arylquinoline and its production
DE19706161A1 (en) * 1997-02-17 1998-08-20 Oswald Hartmut Prof Dr Med Use of cyanines, isocyanines and pseudoisocyanines as diuretics
KR100744826B1 (en) * 2006-04-05 2007-08-01 한국화학연구원 Quinolinone derivatives substituted with imidazole group
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP3239170B1 (en) 2008-06-04 2019-03-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN103804349A (en) * 2012-11-01 2014-05-21 杨子娇 Compounds for treatment of glaucoma and their use
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
JP6606491B2 (en) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド Ultra high purity agonist of guanylate cyclase C, method for producing and using the same
CN108558750B (en) * 2018-07-11 2021-01-05 武汉工程大学 Process for synthesizing 3-nitroquinoline derivative by solvent-free method

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94390A (en) * 1989-05-30 1996-03-31 Merck & Co Inc Di-substituted imidazo fused 6-membered nitrogen-containing heterocycles and pharmaceutical compositions containing them
MX9200299A (en) * 1991-02-07 1992-12-01 Roussel Uclaf NEW NITROGENATED BICYCLE DERIVATIVES, THEIR PROCEDURE FOR PREPARING THE NEW INTERMEDIATE COMPOUNDS OBTAINED THEIR APPLICATION AS MEDICINES AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
DE4117750A1 (en) * 1991-05-30 1992-12-24 Bayer Ag NEW 2-AMINO-5-CYANO-1,4-DIHYDROPYRIDINE, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICINAL PRODUCTS
EP0528762B1 (en) * 1991-08-15 1997-05-07 Novartis AG N-acyl-N-heterocyclyl- or naphthyl-alkyl amino acids as angiotensin II antagonists

Also Published As

Publication number Publication date
JPH05239053A (en) 1993-09-17
ZA928297B (en) 1993-05-07
CZ324292A3 (en) 1993-09-15
DE69204252D1 (en) 1995-09-28
PL296369A1 (en) 1993-05-31
NZ244892A (en) 1994-06-27
IL103568A0 (en) 1993-03-15
FI924869A (en) 1993-04-29
FI924869A0 (en) 1992-10-27
AU651740B2 (en) 1994-07-28
CA2081537A1 (en) 1993-04-29
HUT62883A (en) 1993-06-28
AU2734892A (en) 1993-04-29
CN1073171A (en) 1993-06-16
NO924138L (en) 1993-04-29
DE69204252T2 (en) 1996-04-18
MX9206169A (en) 1993-07-01
EP0540400A1 (en) 1993-05-05
FR2683819A1 (en) 1993-05-21
ATE126798T1 (en) 1995-09-15
EP0540400B1 (en) 1995-08-23
HU9203374D0 (en) 1993-01-28
FR2683819B1 (en) 1994-02-11
KR930007935A (en) 1993-05-20

Similar Documents

Publication Publication Date Title
NO924138D0 (en) CHINOLINE DERIVATIVES, THE PROCEDURE FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
DE69103206T2 (en) New derivatives of aminopiperidine, aminopyrrolidine and aminoperhydroazepine, process for their preparation and medicaments containing them.
DK0500409T3 (en) Derivatives of 4-pyrimidinols, their preparation and use in therapy
DE69116930D1 (en) Fluorinated bis (hydroxymethyl) cyclobutylpurines and pyrimidines
GB2110669B (en) Imidazolidinones
DK0508955T3 (en) Use of 2-iminothiazolidine-4-derivatives as novel drugs
DK599486D0 (en) 1,4-DIHYDROPYRIDINES, THEIR PREPARATION OF USE AS MEDICINAL PRODUCTS
ATE134607T1 (en) TETRAHYDRONAPHTALENE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
DE69320542D1 (en) Pyrrolothienopyrazine compounds as 5HT3 receptor antagonists